IT1255258B - Composizioni farmaceutiche per l'applicazione per via nasale. - Google Patents

Composizioni farmaceutiche per l'applicazione per via nasale.

Info

Publication number
IT1255258B
IT1255258B ITRM910696A ITRM910696A IT1255258B IT 1255258 B IT1255258 B IT 1255258B IT RM910696 A ITRM910696 A IT RM910696A IT RM910696 A ITRM910696 A IT RM910696A IT 1255258 B IT1255258 B IT 1255258B
Authority
IT
Italy
Prior art keywords
pharmaceutical compositions
nasal application
nasal
application
hpth
Prior art date
Application number
ITRM910696A
Other languages
English (en)
Inventor
Francois Cardinaux
Christine Oechslein
Andreas Rummelt
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of ITRM910696A0 publication Critical patent/ITRM910696A0/it
Publication of ITRM910696A1 publication Critical patent/ITRM910696A1/it
Application granted granted Critical
Publication of IT1255258B publication Critical patent/IT1255258B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invenzione riguarda una composizione farmaceutica adattata per la somministrazione per via nasale e comprendente l'hPTH o un frammento N-terminale di questo composto. I veicoli preferiti sono le cellulose eventualmente rivestite.
ITRM910696A 1990-09-20 1991-09-18 Composizioni farmaceutiche per l'applicazione per via nasale. IT1255258B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020544A GB9020544D0 (en) 1990-09-20 1990-09-20 Improvements in or relating to organic compounds

Publications (3)

Publication Number Publication Date
ITRM910696A0 ITRM910696A0 (it) 1991-09-18
ITRM910696A1 ITRM910696A1 (it) 1993-03-18
IT1255258B true IT1255258B (it) 1995-10-20

Family

ID=10682494

Family Applications (1)

Application Number Title Priority Date Filing Date
ITRM910696A IT1255258B (it) 1990-09-20 1991-09-18 Composizioni farmaceutiche per l'applicazione per via nasale.

Country Status (21)

Country Link
US (1) US5578567A (it)
EP (2) EP0490806A3 (it)
JP (1) JPH04247034A (it)
KR (1) KR920006003A (it)
AT (1) ATA189691A (it)
AU (1) AU8464791A (it)
CA (1) CA2051721A1 (it)
CH (1) CH683749A5 (it)
CS (1) CS285491A3 (it)
DE (1) DE4131232A1 (it)
FI (1) FI914398A (it)
FR (2) FR2666987A1 (it)
GB (2) GB9020544D0 (it)
IE (1) IE913296A1 (it)
IL (1) IL99521A0 (it)
IT (1) IT1255258B (it)
LU (1) LU88006A1 (it)
MX (1) MX9101175A (it)
NO (1) NO913668D0 (it)
PT (1) PT99007A (it)
ZA (1) ZA917528B (it)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090353B2 (ja) * 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
DE69228828T2 (de) * 1991-12-09 1999-12-16 Asahi Chemical Ind Stabilisierte parathormonzusammensetzung
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
EP0566135A1 (en) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosal composition comprising a peptide and a cytidine derivative
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
KR100291620B1 (ko) 1992-09-29 2001-10-24 추후제출 부갑상선호르몬의활성단편의폐를통한전달방법
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
AU703532B2 (en) * 1994-12-22 1999-03-25 Astra Aktiebolag Therapeutic preparation for inhalation containing parathyroid hormone, PTH
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
CA2208336A1 (en) * 1996-06-20 1997-12-20 Hisamitsu Pharmaceuticals Co., Inc. A device structure for iontophoresis
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20020094951A1 (en) * 1997-07-22 2002-07-18 Noboru Horiuchi Dental remedies containing pth
ATE417927T1 (de) 1997-07-30 2009-01-15 Univ Emory Neue knochenmineralisierungsproteine, dna, vektoren, expressionssysteme
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
MY120063A (en) † 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1065141C (zh) * 1998-05-20 2001-05-02 北京金源东和化学有限责任公司 通过鼻粘膜给药的药物制剂
US6623732B1 (en) * 1998-05-20 2003-09-23 Highchem Company, Ltd. Pharmaceutical formulation for nasal administration
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
DE69932144T8 (de) * 1998-08-26 2007-10-04 Teijin Ltd. Pulverförmige pernasale mittel
JP2000239187A (ja) 1999-02-22 2000-09-05 Dotto:Kk 経鼻吸収用組成物
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
CA2370853C (en) * 1999-05-03 2007-07-10 Battelle Memorial Institute Compositions for aerosolization and inhalation
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
ES2166278B2 (es) * 1999-09-14 2003-06-16 Univ Madrid Complutense Procedimiento de preparacion de polvos nasales por atomizacion utilizando excipientes insolubles y absorbentes como promotores de absorcion nasal.
WO2001074431A2 (en) * 2000-04-03 2001-10-11 Battelle Memorial Institute Dispensing devices and liquid formulations
US7087248B2 (en) 2000-06-30 2006-08-08 Daiichi Asubio Pharma Co., Ltd. Pharmaceutical component based on human parathyroid hormone and a pharmaceutical composition for intranasal administration comprising the component
AU3664102A (en) * 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
DE10120200B4 (de) * 2001-04-24 2005-12-22 Infood Gmbh Schnupfpulver als Schnupftabakersatz
CN100522245C (zh) * 2002-05-23 2009-08-05 Umd公司 用于穿粘膜的药物输送和冷冻保护的组合物
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003286472A1 (en) 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
JP2007537274A (ja) * 2004-05-10 2007-12-20 ナステック ファーマスーティカル カンパニー インク． 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
CN101005851A (zh) * 2004-07-14 2007-07-25 中外制药株式会社 含pth的经粘膜给药药剂
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
WO2006091332A2 (en) * 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
CA2611836A1 (en) * 2005-06-13 2006-12-21 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
AU2006299887A1 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. PTH formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
CA2628945A1 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
EP2106788A1 (en) * 2008-04-04 2009-10-07 Ipsen Pharma Liquid and freeze dried formulations
JP2013512688A (ja) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ クロクマの副甲状腺ホルモン及びクロクマの副甲状腺ホルモンを使用する方法
JP5670430B2 (ja) * 2010-03-19 2015-02-18 第一三共株式会社 経鼻投与用組成物及びその製造方法
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US11124479B2 (en) 2017-07-14 2021-09-21 New York University Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
US10500197B2 (en) 2017-07-18 2019-12-10 New York University Use of oligopyridylamides to inhibit mutant p53 amyloid formation and restore its tumor suppressor function
WO2021229835A1 (ja) * 2020-05-11 2021-11-18 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
WO2022159593A1 (en) * 2021-01-21 2022-07-28 Nbo Pharma Llc Intranasal formulations and delivery of somatostatin mimetics and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JPS63243033A (ja) * 1987-03-31 1988-10-07 Toyo Jozo Co Ltd 経鼻投与組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
EP0312052B1 (en) * 1987-10-15 1994-01-05 Syntex (U.S.A.) Inc. Intranasal administration of polypeptides in powdered form
EP0327756B1 (en) * 1987-11-13 1994-01-26 Smithkline Beecham Farmaceutici S.p.A. Pharmaceutical compositions comprising a calcitonin and a glycyrrhizinate as absorption enhancer
JPH0242027A (ja) * 1988-08-02 1990-02-13 Minofuaagen Seiyaku Honpo:Goushi 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
AU647735B2 (en) * 1989-03-08 1994-03-31 University Of Virginia Alumni Patents Foundation, The Dietary supplement for insulin-resistant diabetics
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment

Also Published As

Publication number Publication date
NO913668D0 (no) 1991-09-18
ITRM910696A1 (it) 1993-03-18
GB2248550A (en) 1992-04-15
ZA917528B (en) 1993-03-22
CH683749A5 (de) 1994-05-13
CS285491A3 (en) 1992-04-15
KR920006003A (ko) 1992-04-27
DE4131232A1 (de) 1992-03-26
AU8464791A (en) 1992-03-26
JPH04247034A (ja) 1992-09-03
IL99521A0 (en) 1992-08-18
EP0490806A2 (en) 1992-06-17
FR2681326B1 (fr) 1995-06-16
US5578567A (en) 1996-11-26
PT99007A (pt) 1992-08-31
GB2248550B (en) 1995-04-05
FI914398A0 (fi) 1991-09-18
EP0490806A3 (en) 1992-09-23
IE913296A1 (en) 1992-02-25
FR2666987A1 (fr) 1992-03-27
GB9020544D0 (en) 1990-10-31
CA2051721A1 (en) 1992-03-21
LU88006A1 (fr) 1993-04-15
GB9120024D0 (en) 1991-11-06
FI914398A (fi) 1992-03-21
MX9101175A (es) 1992-05-04
EP0672682A1 (en) 1995-09-20
ITRM910696A0 (it) 1991-09-18
ATA189691A (de) 1997-10-15
FR2681326A1 (fr) 1993-03-19

Similar Documents

Publication Publication Date Title
IT1255258B (it) Composizioni farmaceutiche per l'applicazione per via nasale.
BR9810495A (pt) Composição farmacêutica
FI973828A (fi) Yhdisteitä ja koostumuksia aktiivisten aineiden annostelemiseksi
ATE260646T1 (de) Schnell zerfallende orale dosierungsform
HUP0100043A2 (hu) Savérzékeny hatóanyagot tartalmazó új gyógyszerforma
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
ES2130575T3 (es) Composiciones inmunogenicas mejoradas contra la gastrina 17 humana.
IL119989A0 (en) Pharmaceutical compositions for oral treatment of multiple sclerosis
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
CA2270177A1 (en) Transdermal administration of ment
FI972434A0 (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
CO4940448A1 (es) Modificacion a cristal de una sustancia de medicamento
SE9403389D0 (sv) Pharmaceutical composition containing derivattves of sex hormones
ATE353224T1 (de) Abgabeeinrichtung für eine zusammensetzung einer pharmazeutisch wirksamen substanz
CA2218643A1 (en) Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
SE8800461L (sv) Farmaceutisk komposition
ES2170377T3 (es) Composicion que contiene quitosana.
IT8722647A0 (it) Composizione farmaceutica per somministrazione nasale.
ATE98478T1 (de) Calcitonin enthaltende pharmazeutische zusammensetzungen.
ATE204286T1 (de) Modifizierte alpha-d-glcp-(1,2)-alpha-d-glcp-(1, 3)-alpha-d-glcp-analoge
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.
KR970701559A (ko) 펩타이드의 경구 투여를 위한 안정화된 조성물(stabilized composition for oral administration of peptides)
ITMI913306A1 (it) Composizioni farmaceutiche per la somministrazione nasale di polipeptidi.
IT8323911A0 (it) Composizione farmaceutica per la somministrazione orale di calcitonina.
FR2685204B1 (fr) Compositions pharmaceutiques pour l'administration transcutanee de la fenfluramine.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970714